GRADE profile 1Endoscopic therapies – studies with follow-up not stated

StudyDesignTreatmentPlaceboRiskLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Primary outcome 2. Complete eradication of Barrett’s oesophagus or intestinal metaplasia
Manner et al. (2007)Uncontrolled104/131 (79.39%)Single-centre study, mainly looking at safety n = 215; relevant+ (Very low)
Adverse outcome 8. Minor adverse events
Manner et al. (2006, 2007)aUncontrolled10.69–11.71%bTwo studies from the same centre n = 111, n = 131+ (Very low)
Adverse outcome 9. Stricture or stenosis needing dilation
Manner et al. (2006, 2007)aUncontrolled0.76–0.96%Two studies from the same centre n = 111, n = 131+ (Very low)
a

Studies used argon plasma coagulation after treatment with endoscopic mucosal resection or endoscopic mucosal resection with photodynamic therapy.

b

Manner et al. (2006); n = 215; 13 cases of minor adverse events occurred: chest pain (7) and fever (6) in the relevant population (n = 111). Manner et al. (2007); n = 216; 14 cases of minor adverse events occurred: pain, dysphagia, cough after argon plasma coagulation, cardiac arrhythmia, gas accumulation in the gastrointestinal wall, neuromuscular irritation.

From: 2, How this guideline was developed

Cover of Barrett’s Oesophagus
Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus.
NICE Clinical Guidelines, No. 106.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.